Radiopharmaceuticals
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global radiopharmaceutical market insights. NovaPharmaNews delivers critical intelligence for investors, BD, and analysts on nuclear medicine innovation.
Showing 1–4 of 4 articles
Quick answer
NovaPharmaNews Radiopharmaceuticals hub for FDA covers 4 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Accord Healthcare Relaunches Tadalafil Tablets in Multiple Dosage Strengths, Expanding Generic ED Treatment Access
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
C-Ray Therapeutics Receives FDA Acceptance for Copper-64 Drug Master File, Advancing Radiopharmaceutical Development
Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.